|
|
激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌一线治疗的研究进展
|
Abstract:
激素受体阳性(HR+)/人类表皮生长因子受体2阴性(HER2？)乳腺癌是最常见的乳腺癌亚型。大约30%的肿瘤在手术后复发和转移，并且约5%~10%的患者在初次诊断时即被诊断为晚期乳腺癌，对于这类乳腺癌，目前可以选择的治疗方案有许多，包括芳香化酶抑制剂(aromatase inhibitors, AI)、选择性雌激素受体下调剂(fulvestrant)细胞周期蛋白依赖性激酶4/6 (cyclin-dependent kinase 4/6, CDK4/6)抑制剂、磷脂酰肌醇-3-激酶(phosphatidylinositiol-3-kinases, PI3K)、丝氨酸/苏氨酸蛋白激酶(proteinserine-threonine kinase, AKT)抑制剂、雷帕霉素靶蛋白(mammalian target of rapamycin, mTOR)抑制剂、组蛋白脱乙酰酶(histone deacetylase, HDAC)抑制剂等。本文以内脏危象为分层就HR+/HER2？型乳腺癌一线治疗方面的研究进行综述，以期为乳腺癌患者的精准治疗提供理论基础。
Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2？) breast cancer is the most common subtype of breast cancer. Approximately 30% of tumors experi-ence recurrence and metastasis after surgery, and about 5%~10% of patients are diagnosed with advanced breast cancer at the initial diagnosis. For this type of breast cancer, there are various treatment options available, including aromatase inhibitors (AI), selective estrogen receptor de-graders (fulvestrant), cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, phosphatidylinositiol- 3-kinases (PI3K), proteinserine-threonine kinase (AKT) inhibitors, mammalian target of rapamycin (mTOR) inhibitors, histone deacetylase (HDAC) inhibitors, and others. This article reviews research on first-line treatment for HR+/HER2？ breast cancer, stratified by visceral crisis, aiming to provide a theoretical basis for precision treatment of breast cancer patients.
| [1] | Sung, H., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660 |
| [2] | Rugo, H.S., et al. (2016) Endocrine Therapy for Hormone Recep-tor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. Journal of Clinical Oncology, 34, 3069-3103. |
| [3] | Turner, N.C., Neven, P., Loibl, S. and Andre, F. (2017) Advances in the Treatment of Advanced Oestrogen-Receptor- Positive Breast Cancer. Lancet, 389, 2403-2414. https://doi.org/10.1016/S0140-6736(16)32419-9 |
| [4] | Reinert, T. and Barrios, C.H. (2015) Optimal Management of Hormone Receptor Positive Metastatic Breast Cancer in 2016. Therapeutic Advances in Medical Oncology, 7, 304-320. https://doi.org/10.1177/1758834015608993 |
| [5] | 国家卫生健康委员会医政医管局. 乳腺癌诊疗指南(2022年版) [J]. 中华肿瘤杂志, 2023, 45(10): 803-833.
https://doi.org/10.3760/cma.j.cn112152-20230706-00281 |
| [6] | Modi, S., et al. (2022) Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. The New England Journal of Medicine, 387, 9-20. https://doi.org/10.1056/NEJMc2210368 |
| [7] | Zardavas, D., Baselga, J. and Piccart, M. (2013) Emerging Targeted Agents in Metastatic Breast Cancer. Nature Reviews Clinical Oncology, 10, 191-210. https://doi.org/10.1038/nrclinonc.2013.29 |
| [8] | Gelmon, K., et al. (2021) Efficacy and Safety of Palbociclib in Pa-tients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer with Preexisting Conditions: A Post Hoc Analysis of PALOMA-2. Breast, 59, 321-326. https://doi.org/10.1016/j.breast.2021.07.017 |
| [9] | Hortobagyi, G.N., et al. (2018) Updated Results from MONALEESA-2, a Phase III Trial of First-Line Ribociclib plus Letrozole versus Placebo plus Letrozole in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer. Annals of Oncology, 29, 1541-1547. https://doi.org/10.1093/annonc/mdy155 |
| [10] | Tripathy, D., et al. (2018) Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-Receptor- Positive, Advanced Breast Cancer (MONALEESA-7): A Randomised Phase 3 Trial. The Lancet Oncology, 19, 904-915. https://doi.org/10.1016/S1470-2045(18)30292-4 |
| [11] | Johnston, S., et al. (2019) MONARCH 3 Final PFS: A Randomized Study of Abemaciclib as Initial Therapy for Advanced Breast Cancer. NPJ Breast Cancer, 5, Article No. 5. https://doi.org/10.1038/s41523-018-0097-z |
| [12] | Goetz, M.P., et al. (2017) MONARCH 3: Abemaciclib as Initial Therapy for Advanced Breast Cancer. Journal of Clinical Oncology, 35, 3638-3646. https://doi.org/10.1200/JCO.2017.75.6155 |
| [13] | Hortobagyi, G.N., et al. (2022) Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. The New England Journal of Medicine, 386, 942-950. https://doi.org/10.1056/NEJMoa2114663 |
| [14] | Lu, Y.S., et al. (2022) Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2？ Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. Clinical Cancer Research, 28, 851-859. https://doi.org/10.1158/1078-0432.CCR-21-3032 |
| [15] | Finn, R.S., et al. () Overall Survival (OS) with First-Line Palbociclib plus Letrozole (PAL + LET) versus Placebo plus Letrozole (PBO + LET) in Women with Estrogen Recep-tor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer (ER+/HER2？ ABC): Anal-yses from PALOMA-2. Journal of Clinical Oncology, 40. |
| [16] | Goetz, M.P., et al. (2022) LBA15 MONARCH 3: In-terim Overall Survival (OS) Results of Abemaciclib plus a Nonsteroidal Aromatase Inhibitor (NSAI) in PATIENTS (pts) with HR+, HER2？ Advanced Breast Cancer (ABC). Annals of Oncology, 33, S1384. https://doi.org/10.1016/j.annonc.2022.08.009 |
| [17] | Breast Cancer Expert Committee of National Cancer Quality Control Center, Breast Cancer Expert Committee of China Anti-Cancer Association and Cancer Drug Clinical Research Committee of China Anti-Cancer Association (2022) [Guidelines for Clinical Diagnosis and Treatment of Advanced Breast Cancer in China (2022 Edition)]. Chinese Journal of Oncology, 44, 1262-1287. |
| [18] | Xu, B., et al. (2021) Effica-cy of Utidelone plus Capecitabine versus Capecitabine for Heavily Pretreated, Anthracycline- and Taxane-Refractory Metastatic Breast Cancer: Final Analysis of Overall Survival in a Phase III Randomised Controlled Trial. Annals of On-cology, 32, 218-228. https://doi.org/10.1016/j.annonc.2020.10.600 |
| [19] | Lu, Y.S., et al. (2023) Abstract GS1-10: Primary Results from the Randomized Phase II RIGHT Choice Trial of Premenopausal Patients with Aggressive HR+/HER2？ Advanced Breast Cancer Treated with Ribociclib + Endocrine Therapy vs Physician’s Choice Combination Chemotherapy. Cancer Research, 83, GS1-10.
https://doi.org/10.1158/1538-7445.SABCS22-GS1-10 https://aacrjournals.org/cancerres/article/83/5_Supplement/GS1-10/717716/Abstract-GS1-10-Primary-results-from-the |
| [20] | Zhang, Q.Y., et al. (2020) MONARCH plus: Abemaciclib plus Endocrine Therapy in Women with HR+/HER2– Advanced Breast Cancer: The Multinational Randomized Phase III Study. Therapeutic Advances in Medi-cal Oncology, 12.
https://doi.org/10.1177/1758835920963925 |
| [21] | Cristofanilli, M., et al. (2016) Fulvestrant plus Palbociclib versus Fulvestrant plus Placebo for Treatment of Hormone-Receptor-Positive, HER2-Negative Metastatic Breast Cancer That Progressed on Previous Endocrine Therapy (PALOMA-3): Final Analysis of the Multicentre, Double-Blind, Phase 3 Randomised Controlled Trial. The Lancet Oncology, 17, 425-439. https://doi.org/10.1016/S1470-2045(15)00613-0 |
| [22] | Loibl, S., et al. (2017) Palbociclib Combined with Fulves-trant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. The Oncologist, 22, 1028-1038.
https://doi.org/10.1634/theoncologist.2017-0072 |
| [23] | Turner, N.C., et al. (2018) Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. The New England Journal of Medicine, 379, 1926-1936. https://doi.org/10.1056/NEJMoa1810527 |
| [24] | Slamon, D.J., et al. (2018) Phase III Randomized Study of Ribo-ciclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. Journal of Clinical Oncology, 36, 2465-2472. https://doi.org/10.1200/JCO.2018.78.9909 |
| [25] | Slamon, D.J., et al. (2020) Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. The New England Journal of Medicine, 382, 514-524. https://doi.org/10.1056/NEJMoa1911149 |
| [26] | Xu, B., et al. (2021) Dalpiciclib or Placebo plus Fulvestrant in Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer: A Randomized, Phase 3 Trial. Nature Medi-cine, 27, 1904-1909.
https://doi.org/10.1038/s41591-021-01562-9 |
| [27] | Jiang, Z., et al. (2019) Tucidinostat plus Exemestane for Post-menopausal Patients with Advanced, Hormone Receptor-Positive Breast Cancer (ACE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 20, 806-815. https://doi.org/10.1016/S1470-2045(19)30164-0 |
| [28] | Piccart, M., et al. (2014) Everolimus plus Exemestane for Hormone-Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: Overall Survival Results from BOLERO-2. Annals of Oncology, 25, 2357-2362. https://doi.org/10.1093/annonc/mdu456 |
| [29] | Yardley, D.A., et al. (2013) Everolimus plus Exemestane in Post-menopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis. Advances in Therapy, 30, 870-884.
https://doi.org/10.1007/s12325-013-0060-1 |
| [30] | André, F., et al. (2019) Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. The New England Journal of Medicine, 380, 1929-1940. https://doi.org/10.1056/NEJMoa1813904 |
| [31] | André, F., et al. (2021) Alpelisib plus Fulvestrant for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: Final Overall Survival Results from SOLAR-1. Annals of Oncology, 32, 208-217. https://doi.org/10.1016/j.annonc.2020.11.011 |
| [32] | André, F., et al. (2020) LBA18 Overall Survival (OS) Results from SOLAR-1, a Phase III Study of Alpelisib (ALP) + Fulvestrant (FUL) for Hormone Receptor-Positive (HR+), Hu-man Epidermal Growth Factor Receptor 2-Negative (HER2？) Advanced Breast Cancer (ABC). Annals of Oncology, 31, S1150-S1151.
https://doi.org/10.1016/j.annonc.2020.08.2246 |
